Dr Alan Cameron

  • Honorary Clinical Lecturer (School of Cardiovascular & Metabolic Health)

email: Alan.Cameron.2@glasgow.ac.uk

Graduate School Office, Room 362, Wolfson Link Building, G12 8qq

Import to contacts

Biography

Dr Alan Cameron is an Honorary Clinical Lecturer and Specialty Registrar in Stroke Medicine. His research focuses on preventing atrial fibrillation (AF)-related strokes through improved AF detection and management. Dr Cameron was awarded a PhD in Cardiovascular Medicine at the University of Glasgow British Heart Foundation Centre of Research Excellence in 2019. He contributes to international stroke guidelines; is a Fellow of the European Stroke Organisation; and a member of the AF Screen International Collaboration. He regularly delivers oral presentations at international/national stroke conferences, including European Stroke Organisation Conferences where he has been awarded a Commendation and Young Investigator Award.

Background

Alan graduated in Medicine from the University of Glasgow in 2010 and achieved an Intercalated BSc in Cardiovascular Medicine with First Class Honours in 2008. He completed early clinical academic training as part of the Glasgow Academic Training Environment (GATE) from 2010 to 2014, and a Clinical Teaching Fellowship in Medicine with Postgraduate Certificate in Health Professions Education (Merit) at the Western Infirmary Glasgow from 2014-15. He was awarded a PhD from the BHF Centre of Research Excellence at the University of Glasgow School of Cardiovascular and Metabolic Health in 2019. Since being awarded his PhD, Alan has worked tirelessly to develop a novel and innovative research programme that aims to improve prevention of AF-related stroke.

Research interests

Dr Cameron has developed a translational research programme that aims to improve selection of people for AF screening to prevent AF-related strokes through prognostic risk scores that include demographics, natriuretic peptide blood biomarkers, artificial intelligence (AI) analysis of electrocardiograms (ECGs) and genetic risk.

AIMS
•     To define the impact of using these biomarkers to guide AF screening pathways.
•     To define the optimal device and duration of cardiac rhythm monitoring to screen for AF in people after stroke.

Dr Cameron has been awarded grants to support his research from funders including the Stroke Association, Heart Research UK, Chief Scientist Office, Royal College of Physicians and Surgeons of Glasgow, Tenovus Scotland, NHS Greater Glasgow and Clyde, The Mason Medical Research Trust and Pfizer. Alan supervises PhD, MSc and BSc students and contributes to undergraduate and postgraduate teaching programmes to help develop the next generation of researchers and clinicians in stroke and cardiovascular medicine.

INVITED TALKS
Cameron AC. Detection of atrial fibrillation after stroke and TIA. UK Stroke Forum 2022.
Cameron AC. Patent foramen ovale closure after stroke. NIHR Stroke Conference 2022.
Cameron AC. Preventing Recurrent Cardioembolic Stroke: Right Approach, Right Patient The PRECISE Study. Caledonian Society of Clinical Pharmacology Annual Meeting 2022.
Cameron AC. Future directions for stroke prevention. UK Stroke Forum 2021.
Cameron AC. Variation in anticoagulation to reduce AF-related stroke – how are we doing? Arrhythmia Alliance Cardiac Update Meeting 2020.

ORAL PRESENTATIONS
Cameron AC, Arnold M, Yang J, et al. Natriuretic peptides can help identify people who do not need prolonged cardiac monitoring after stroke. European Stroke Organisation Conference 2023, Munich.
Cameron AC, Arnold M, Cheng HK, et al. Natriuretic peptides improve the performance of atrial fibrillation risk scores: data from the BIOSIGNAL cohort. European Stroke Organisation Conference 2022, Lyon/Virtual.
Cameron AC, Cheng HK, Lee RP, et al. Clinical, ECG and blood based biomarkers associated with AF detection during cardiac monitoring after stroke or TIA: a systematic review and meta-analysis. Stroke 2020, Royal College of Physicians and Surgeons of Glasgow.
Cameron AC, Abdul-Rahim AH, Bogie J, et al. Alteplase Dose for Acute Ischaemic Stroke: Higher Absolute Doses are Associated with Favourable Functional Outcomes and Survival. 4th European Stroke Organisation Conference 2018, Gothenburg.
Cameron AC, Bogie J, Abdul-Rahim AH, et al. Professional guideline versus product licence selection for treatment with IV thrombolysis: compliance with product licences is highest in lower efficiency sites and restricts thrombolysis usage. 3rd European Stroke Organisation Conference 2017, Prague.
Cameron AC, Lees KR, Booth MG, et al. A survey of principal researchers who lead research into Adults with Incapacity in Scotland. 10th Congress of the European Association for Clinical Pharmacology and Therapeutics 2011, Vienna.

Publications

List by: Type | Date

Jump to: 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015
Number of items: 27.

2023

Cameron, A. C., Lip, G. Y. H. and Abdul‐Rahim, A. H. (2023) Machine‐learning derived heart and brain age are independently associated with cognition. European Journal of Neurology, (doi: 10.1111/ene.15953) (PMID:37353892) (Early Online Publication)

Cameron, A. C. and Abdul-Rahim, A. H. (2023) Editorial: the optimal management for people with acute stroke and minor deficits - intravenous thrombolysis or medical management? Thrombosis and Haemostasis, (doi: 10.1055/a-2077-5642) (PMID:37075783) (Early Online Publication)

Alamowitch, S. et al. (2023) European Stroke Organisation (ESO) expedited recommendation on tenecteplase for acute ischaemic stroke. European Stroke Journal, 8(1), pp. 8-54. (doi: 10.1177/23969873221150022) (PMID:37021186) (PMCID:PMC10069183)

Dawson, J. et al. (2023) Xanthine oxidase inhibition and white matter hyperintensity progression following ischaemic stroke and transient ischaemic attack (XILO-FIST): a multicentre, double-blinded, randomised, placebo-controlled trial. EClinicalMedicine, 57, 101863. (doi: 10.1016/j.eclinm.2023.101863) (PMID:36864979) (PMCID:PMC9972492)

2022

Johnston, F. C., Cameron, A. C., Colquhoun, E., Murdoch, D. L., Dawson, J. and Abdul-Rahim, A. H. (2022) Improving detection and management of atrial fibrillation after ischaemic stroke in Glasgow (IMPROVE-AF): a quality improvement project. Journal of the Royal College of Physicians of Edinburgh, 52(3), pp. 213-219. (doi: 10.1177/14782715221120133) (PMID:36369810)

Kishore, A. K., Hossain, M. J., Cameron, A., Dawson, J. , Vail, A. and Smith, C. J. (2022) Use of risk scores for predicting new atrial fibrillation after ischemic stroke or transient ischemic attack—A systematic review. International Journal of Stroke, 17(6), pp. 608-617. (doi: 10.1177/17474930211045880) (PMID:34551649)

2021

Zuber, V., Cameron, A., Myserlis, E. P., Bottolo, L., Fernandez‐Cadenas, I., Burgess, S., Anderson, C. D., Dawson, J. and Gill, D. (2021) Leveraging genetic data to elucidate the relationship between COVID‐19 and ischemic stroke. Journal of the American Heart Association, 10(22), e022433. (doi: 10.1161/JAHA.121.022433) (PMID:34755518)

Cameron, A., Cheng, H. K., Lee, R.-P., Doherty, D., Hall, M., Khashayar, P., Lip, G., Quinn, T., Abdul-Rahim, A. and Dawson, J. (2021) Biomarkers for atrial fibrillation detection after stroke: systematic review and meta-analysis. Neurology, 97(18), e1775-e1789. (doi: 10.1212/WNL.0000000000012769) (PMID:34504030)

Cameron, A. C., Neves, K. B. , White, J., Touyz, R. M. and Lang, N. N. (2021) Reply: Cisplatin-associated aortic thrombosis: a review of cases reported to the FDA adverse event reporting system. JACC: CardioOncology, 3(1), p. 166. (doi: 10.1016/j.jaccao.2021.01.005)

Gill, D. et al. (2021) Urate, blood pressure, and cardiovascular disease: evidence from Mendelian randomization and meta-analysis of clinical trials. Hypertension, 77(2), pp. 383-392. (doi: 10.1161/HYPERTENSIONAHA.120.16547) (PMID:33356394) (PMCID:PMC7803439)

2020

Steinthorsdottir, V. et al. (2020) Genetic predisposition to hypertension is associated with preeclampsia in European and Central Asian women. Nature Communications, 11, 5976. (doi: 10.1038/s41467-020-19733-6) (PMID:33239696) (PMCID:PMC7688949)

Cameron, A. C. et al. (2020) Comprehensive characterisation of the vascular effects of cisplatin-based chemotherapy in patients with testicular cancer. JACC: CardioOncology, 2(3), pp. 443-455. (doi: 10.1016/j.jaccao.2020.06.004) (PMID:33043304) (PMCID:PMC7539369)

Yu, W. M., Abdul-Rahim, A. , Cameron, A., Kõrv, J., Sevcik, P., Toni, D. and Lees, K. (2020) The incidence and associated factors of early neurological deterioration after thrombolysis: Results from SITS Registry. Stroke, 51(9), pp. 2705-2714. (doi: 10.1161/STROKEAHA.119.028287) (PMID:32811373)

Mentel, A., Quinn, T. J. , Cameron, A. C., Lees, K. R. and Abdul-Rahim, A. H. (2020) The impact of atrial fibrillation type on the risks of thromboembolic recurrence, mortality and major haemorrhage in patients with previous stroke: a systematic review and meta-analysis of observational studies. European Stroke Journal, 5(2), pp. 155-168. (doi: 10.1177/2396987319896674) (PMID:32637649) (PMCID:32637649)

Cameron, A. C., Welsh, P. , Neves, K. B. , Newby, D., Touyz, R. M. and Lang, N. (2020) Acute vascular effects of vascular endothelial growth factor inhibition in the forearm arterial circulation. Journal of Hypertension, 38(2), pp. 257-265. (doi: 10.1097/HJH.0000000000002230) (PMID:31449168) (PMCID:PMC7197298)

2019

Cameron, A. C. et al. (2019) Progressive hypertension and severe left ventricular outflow tract obstruction. Hypertension, 74(6), pp. 1216-1225. (doi: 10.1161/hypertensionaha.119.13343) (PMID:31587571)

Sharma, V. et al. (2019) Report from the Annual Conference of the British Society of Echocardiography, November 2017, Edinburgh International Conference Centre, Edinburgh. Echo Research and Practice, 6(4), M1-M2. (doi: 10.1530/ERP-19-0056)

Cameron, A.C., Dominiczak, A.F. and Touyz, R.M. (2019) Hypertension. In: Touyz, R.M. and Delles, C. (eds.) Textbook of Vascular Medicine. Springer Nature Switzerland: Cham, Switzerland, pp. 331-341. ISBN 9783030164805 (doi: 10.1007/978-3-030-16481-2_31)

Cameron, A. C., Rossitto, G., Lang, N. N. and Touyz, R. M. (2019) Antihypertensive drugs and vascular health. In: Zimlichman, R., Julius, S. and Mancia, G. (eds.) Prehypertension and Cardiometabolic Syndrome. Series: Updates in hypertension and cardiovascular protection. Springer, pp. 585-605. ISBN 9783319753096 (doi: 10.1007/978-3-319-75310-2_37)

Cameron, A. C., Touyz, R. M. and Lang, N. N. (2019) Vascular biology of cancer chemotherapeutic drugs. In: Touyz, R. M. and Delles, C. (eds.) Textbook of Vascular Medicine. Springer: Cham, pp. 259-268. ISBN 9783030164805 (doi: 10.1007/978-3-030-16481-2_24)

2018

Dobbin, S. J.H. , Cameron, A. C., Petrie, M. C. , Jones, R. J. , Touyz, R. M. and Lang, N. N. (2018) Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors. Heart, 104(24), pp. 1995-2002. (doi: 10.1136/heartjnl-2018-313726) (PMID:30228246) (PMCID:PMC6268130)

Neves, K. B. , Rios, F. J. , Van Der Mey, L., Alves-Lopes, R. , Cameron, A. C., Volpe, M., Montezano, A. C., Savoia, C. and Touyz, R. M. (2018) VEGFR (vascular endothelial growth factor receptor) inhibition induces cardiovascular damage via redox-sensitive processes. Hypertension, 71(4), pp. 638-647. (doi: 10.1161/HYPERTENSIONAHA.117.10490) (PMID:29483228)

Cameron, A. C., Bogie, J., Abdul-Rahim, A. H. , Ahmed, N., Mazya, M., Mikulik, R., Hacke, W. and Lees, K. R. (2018) Professional guideline versus product label selection for treatment with IV thrombolysis: an analysis from SITS registry. European Stroke Journal, 3(1), pp. 39-46. (doi: 10.1177/2396987317747737)

2017

Cameron, A. C., Lang, N. N. and Touyz, R. M. (2017) Cardiovascular complications from cancer therapy: hypertension-focus on vascular endothelial growth factor inhibitors. In: Herrmann, J. (ed.) Clinical Cardio-oncology. Elesvier: Amsterdam, pp. 185-211. ISBN 9780323442275 (doi: 10.1016/B978-0-323-44227-5.00010-7)

2016

Cameron, A. C., Lang, N. N. and Touyz, R. M. (2016) Drug treatment of hypertension: focus on vascular health. Drugs, 76(16), pp. 1529-1550. (doi: 10.1007/s40265-016-0642-8) (PMID:27667708)

2015

Cameron, A. C., Touyz, R. M. and Lang, N. N. (2015) Vascular complications of cancer chemotherapy. Canadian Journal of Cardiology, 32(7), pp. 852-862. (doi: 10.1016/j.cjca.2015.12.023) (PMID:26968393) (PMCID:PMC4989034)

Cameron, A. C., Mccallum, L., Gardiner, T., Darroch, C., Walters, M. R. and Oldroyd, K. G. (2015) Impact of treatment algorithms on the prescribing of antithrombotic therapy in patients with suspected acute coronary syndrome - a prospective audit. British Journal of Clinical Pharmacology, 80(5), pp. 1176-1184. (doi: 10.1111/bcp.12714) (PMID:26147691)

This list was generated on Thu Feb 29 08:27:13 2024 GMT.
Number of items: 27.

Articles

Cameron, A. C., Lip, G. Y. H. and Abdul‐Rahim, A. H. (2023) Machine‐learning derived heart and brain age are independently associated with cognition. European Journal of Neurology, (doi: 10.1111/ene.15953) (PMID:37353892) (Early Online Publication)

Cameron, A. C. and Abdul-Rahim, A. H. (2023) Editorial: the optimal management for people with acute stroke and minor deficits - intravenous thrombolysis or medical management? Thrombosis and Haemostasis, (doi: 10.1055/a-2077-5642) (PMID:37075783) (Early Online Publication)

Alamowitch, S. et al. (2023) European Stroke Organisation (ESO) expedited recommendation on tenecteplase for acute ischaemic stroke. European Stroke Journal, 8(1), pp. 8-54. (doi: 10.1177/23969873221150022) (PMID:37021186) (PMCID:PMC10069183)

Dawson, J. et al. (2023) Xanthine oxidase inhibition and white matter hyperintensity progression following ischaemic stroke and transient ischaemic attack (XILO-FIST): a multicentre, double-blinded, randomised, placebo-controlled trial. EClinicalMedicine, 57, 101863. (doi: 10.1016/j.eclinm.2023.101863) (PMID:36864979) (PMCID:PMC9972492)

Johnston, F. C., Cameron, A. C., Colquhoun, E., Murdoch, D. L., Dawson, J. and Abdul-Rahim, A. H. (2022) Improving detection and management of atrial fibrillation after ischaemic stroke in Glasgow (IMPROVE-AF): a quality improvement project. Journal of the Royal College of Physicians of Edinburgh, 52(3), pp. 213-219. (doi: 10.1177/14782715221120133) (PMID:36369810)

Kishore, A. K., Hossain, M. J., Cameron, A., Dawson, J. , Vail, A. and Smith, C. J. (2022) Use of risk scores for predicting new atrial fibrillation after ischemic stroke or transient ischemic attack—A systematic review. International Journal of Stroke, 17(6), pp. 608-617. (doi: 10.1177/17474930211045880) (PMID:34551649)

Zuber, V., Cameron, A., Myserlis, E. P., Bottolo, L., Fernandez‐Cadenas, I., Burgess, S., Anderson, C. D., Dawson, J. and Gill, D. (2021) Leveraging genetic data to elucidate the relationship between COVID‐19 and ischemic stroke. Journal of the American Heart Association, 10(22), e022433. (doi: 10.1161/JAHA.121.022433) (PMID:34755518)

Cameron, A., Cheng, H. K., Lee, R.-P., Doherty, D., Hall, M., Khashayar, P., Lip, G., Quinn, T., Abdul-Rahim, A. and Dawson, J. (2021) Biomarkers for atrial fibrillation detection after stroke: systematic review and meta-analysis. Neurology, 97(18), e1775-e1789. (doi: 10.1212/WNL.0000000000012769) (PMID:34504030)

Cameron, A. C., Neves, K. B. , White, J., Touyz, R. M. and Lang, N. N. (2021) Reply: Cisplatin-associated aortic thrombosis: a review of cases reported to the FDA adverse event reporting system. JACC: CardioOncology, 3(1), p. 166. (doi: 10.1016/j.jaccao.2021.01.005)

Gill, D. et al. (2021) Urate, blood pressure, and cardiovascular disease: evidence from Mendelian randomization and meta-analysis of clinical trials. Hypertension, 77(2), pp. 383-392. (doi: 10.1161/HYPERTENSIONAHA.120.16547) (PMID:33356394) (PMCID:PMC7803439)

Steinthorsdottir, V. et al. (2020) Genetic predisposition to hypertension is associated with preeclampsia in European and Central Asian women. Nature Communications, 11, 5976. (doi: 10.1038/s41467-020-19733-6) (PMID:33239696) (PMCID:PMC7688949)

Cameron, A. C. et al. (2020) Comprehensive characterisation of the vascular effects of cisplatin-based chemotherapy in patients with testicular cancer. JACC: CardioOncology, 2(3), pp. 443-455. (doi: 10.1016/j.jaccao.2020.06.004) (PMID:33043304) (PMCID:PMC7539369)

Yu, W. M., Abdul-Rahim, A. , Cameron, A., Kõrv, J., Sevcik, P., Toni, D. and Lees, K. (2020) The incidence and associated factors of early neurological deterioration after thrombolysis: Results from SITS Registry. Stroke, 51(9), pp. 2705-2714. (doi: 10.1161/STROKEAHA.119.028287) (PMID:32811373)

Mentel, A., Quinn, T. J. , Cameron, A. C., Lees, K. R. and Abdul-Rahim, A. H. (2020) The impact of atrial fibrillation type on the risks of thromboembolic recurrence, mortality and major haemorrhage in patients with previous stroke: a systematic review and meta-analysis of observational studies. European Stroke Journal, 5(2), pp. 155-168. (doi: 10.1177/2396987319896674) (PMID:32637649) (PMCID:32637649)

Cameron, A. C., Welsh, P. , Neves, K. B. , Newby, D., Touyz, R. M. and Lang, N. (2020) Acute vascular effects of vascular endothelial growth factor inhibition in the forearm arterial circulation. Journal of Hypertension, 38(2), pp. 257-265. (doi: 10.1097/HJH.0000000000002230) (PMID:31449168) (PMCID:PMC7197298)

Cameron, A. C. et al. (2019) Progressive hypertension and severe left ventricular outflow tract obstruction. Hypertension, 74(6), pp. 1216-1225. (doi: 10.1161/hypertensionaha.119.13343) (PMID:31587571)

Sharma, V. et al. (2019) Report from the Annual Conference of the British Society of Echocardiography, November 2017, Edinburgh International Conference Centre, Edinburgh. Echo Research and Practice, 6(4), M1-M2. (doi: 10.1530/ERP-19-0056)

Dobbin, S. J.H. , Cameron, A. C., Petrie, M. C. , Jones, R. J. , Touyz, R. M. and Lang, N. N. (2018) Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors. Heart, 104(24), pp. 1995-2002. (doi: 10.1136/heartjnl-2018-313726) (PMID:30228246) (PMCID:PMC6268130)

Neves, K. B. , Rios, F. J. , Van Der Mey, L., Alves-Lopes, R. , Cameron, A. C., Volpe, M., Montezano, A. C., Savoia, C. and Touyz, R. M. (2018) VEGFR (vascular endothelial growth factor receptor) inhibition induces cardiovascular damage via redox-sensitive processes. Hypertension, 71(4), pp. 638-647. (doi: 10.1161/HYPERTENSIONAHA.117.10490) (PMID:29483228)

Cameron, A. C., Bogie, J., Abdul-Rahim, A. H. , Ahmed, N., Mazya, M., Mikulik, R., Hacke, W. and Lees, K. R. (2018) Professional guideline versus product label selection for treatment with IV thrombolysis: an analysis from SITS registry. European Stroke Journal, 3(1), pp. 39-46. (doi: 10.1177/2396987317747737)

Cameron, A. C., Lang, N. N. and Touyz, R. M. (2016) Drug treatment of hypertension: focus on vascular health. Drugs, 76(16), pp. 1529-1550. (doi: 10.1007/s40265-016-0642-8) (PMID:27667708)

Cameron, A. C., Touyz, R. M. and Lang, N. N. (2015) Vascular complications of cancer chemotherapy. Canadian Journal of Cardiology, 32(7), pp. 852-862. (doi: 10.1016/j.cjca.2015.12.023) (PMID:26968393) (PMCID:PMC4989034)

Cameron, A. C., Mccallum, L., Gardiner, T., Darroch, C., Walters, M. R. and Oldroyd, K. G. (2015) Impact of treatment algorithms on the prescribing of antithrombotic therapy in patients with suspected acute coronary syndrome - a prospective audit. British Journal of Clinical Pharmacology, 80(5), pp. 1176-1184. (doi: 10.1111/bcp.12714) (PMID:26147691)

Book Sections

Cameron, A.C., Dominiczak, A.F. and Touyz, R.M. (2019) Hypertension. In: Touyz, R.M. and Delles, C. (eds.) Textbook of Vascular Medicine. Springer Nature Switzerland: Cham, Switzerland, pp. 331-341. ISBN 9783030164805 (doi: 10.1007/978-3-030-16481-2_31)

Cameron, A. C., Rossitto, G., Lang, N. N. and Touyz, R. M. (2019) Antihypertensive drugs and vascular health. In: Zimlichman, R., Julius, S. and Mancia, G. (eds.) Prehypertension and Cardiometabolic Syndrome. Series: Updates in hypertension and cardiovascular protection. Springer, pp. 585-605. ISBN 9783319753096 (doi: 10.1007/978-3-319-75310-2_37)

Cameron, A. C., Touyz, R. M. and Lang, N. N. (2019) Vascular biology of cancer chemotherapeutic drugs. In: Touyz, R. M. and Delles, C. (eds.) Textbook of Vascular Medicine. Springer: Cham, pp. 259-268. ISBN 9783030164805 (doi: 10.1007/978-3-030-16481-2_24)

Cameron, A. C., Lang, N. N. and Touyz, R. M. (2017) Cardiovascular complications from cancer therapy: hypertension-focus on vascular endothelial growth factor inhibitors. In: Herrmann, J. (ed.) Clinical Cardio-oncology. Elesvier: Amsterdam, pp. 185-211. ISBN 9780323442275 (doi: 10.1016/B978-0-323-44227-5.00010-7)

This list was generated on Thu Feb 29 08:27:13 2024 GMT.

Grants

Grants and Awards listed are those received whilst working with the University of Glasgow.

  • Preventing Recurrent Cardioembolic Stroke - New Blood Tests and Risk Prediction (The PRECISE Study).
    NHS Greater Glasgow and Clyde Endowment Funds
    2023 - 2025
     
  • AF Screening to Prevent Ischaemic StRokE (The ASPIRE Study) - The Role of Blood, ECG and Genetic Biomarkers
    Stroke Association
    2023 - 2025
     
  • Preventing Recurrent Cardioembolic Stroke - Right Approach, Right Patient
    Heart Research UK
    2021 - 2024
     
  • Extended Cardiac Monitoring to Detect Atrial Fibrillation after Stroke - The Harder You Look, The More You Will Find?
    Pfizer
    2021 - 2023
     
  • Preventing Recurrent Cardioembolic Stroke ¿ Right Approach, Right Patient
    Mason Medical Research Foundation
    2021 - 2023
     
  • Preventing Recurrent Cardioembolic Stroke ¿ Right Approach, Right Patient
    Royal College of Physicians and Surgeons of Glasgow
    2021 - 2023
     
  • Preventing Recurrent Cardioembolic Stroke¿
    NHS Greater Glasgow and Clyde Endowment Funds
    2021 - 2023
     
  • Preventing Recurrent Cardioembolic Stroke - Right Approach, Right Patient
    Tenovus Scotland
    2021 - 2022
     
  • Cancer Chemotherapeutics and the Vasculature - Endothelial Effects of VEGF Inhibitorsion In Vivo in Man
    Chief Scientist Office
    2016 - 2018
     
  • Intermediate and Long Term Vascular Effects of Cisplatin in Patients with Testicular Cancer (INTELLECT)
    Mason Medical Research Foundation
    2016 - 2018